-
Mallinckrodt amps up hospital business with $1.3B Therakos buyMallinckrodt has made its second buy of the year--and the company believes it's the perfect match for its first purchase. The Irish drugmaker agreed to fork over about $1.33 billion to investment fir2015/8/11
-
Novartis and Cyndi Lauper just want psoriasis patients to have funNovartis ($NVS) is working hard to build up market share for new psoriasis medCosentyxahead of its forthcoming competition, and it's signed on '80s icon Cyndi Lauper to help. Lauper and the National P2015/8/11
-
Actavis gets subpoena as DOJ probe of generic pricing moves up food chainAllergan ($AGN) may be shedding its background as a generic drug company with a name change and a $40 billion deal to sell that piece of its business, but it hasn't eluded federal investigators intent2015/8/10
-
Amarin wins injunction against FDA in free speech caseOn Friday, Amarin ($AMRN) won what was being called a First Amendment free speech victory for drugmakers. It got a federal court to say the FDA cannot bar Amarin from discussing off-label use of its f2015/8/10
-
Short-sellers target Bavarian Nordic and its cancer vaccine candidateAs it works to bring its prostatecancer vaccineProstvac to market and expand its smallpox vaccine business, Danish vaccine makerBavarian Nordic encountered a new set of challenges this week. Despite a2015/8/7
-
Mylan CEO Bresch: We want Perrigo--but we don't need itPerrigo CEO Joseph Papa said this week that he doesn't intend to make it easy for Mylan to pull off a hostile takeover of his company. But the way Mylan sees it, if it loses out, it's not the end of t2015/8/7
-
Novo Nordisk launches diabetes 'dream team' contest with NBA star as a prizeFormer NBA star Dominique Wilkins is not just a spokesman for Novo Nordisk's ($NVO)Victoza. He's also a prize in a Type 2 diabetes sweepstakes the drugmaker is rolling out. Through the company's "Diab2015/8/6
-
With $300M spent on potential split, Pfizer CEO now 'biased' toward branded M&ANow that Hospira's ($HSP) in the bag, Pfizer ($PFE) execs have less of an appetite for M&A in their Established Products unit. That $16 billion deal gives Pfizer added heft in injectable generics,2015/8/6
-
DME data helps Eylea soar in Q2--and poach market share from its Roche rivalsEarlier this year, Regeneron ($REGN) scored a win when its eye drugEyleaoutperformed a pair of Roche ($RHHBY) meds in a head-to-head study. And now, that win is paying off. Revenue doubled for the Ta2015/8/5
-
Baxalta to Shire: We're young, we're just starting to grow, and we're rejecting your buyout offerTuesday, Shire went public with a $30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer: It's not happening. Shire's $45.23-per-shar2015/8/5